CSL Seqirus
51 articles about CSL Seqirus
-
CSL Seqirus Proud to Attend and Present at 2023 Canadian Immunization Conference
4/25/2023
CSL Seqirus, a global leader in influenza prevention, announced the presentation of data from two Canadian studies at the 2023 Canadian Immunization Conference in Ottawa, Ontario.
-
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
2/28/2023
Amarin Corporation plc (NASDAQ:AMRN) and CSL Seqirus today announced that the two companies have entered into an exclusive license and distribution agreement under which Amarin will license exclusive rights to VAZKEPA to CSL Seqirus to secure pricing and reimbursement and commercialize the product across Australia and New Zealand.
-
San Diego-based Arcturus Therapeutics signed a strategic collaboration and licensing deal with CSL Seqirus to help develop and commercialize vaccines. -
CSL Seqirus Announces U.S. Government Award to Manufacture and Clinically Assess Influenza A(H5N8) Pre-Pandemic Vaccine
10/6/2022
CSL Seqirus announced that the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, selected CSL Seqirus to deliver an H5N8 A/Astrakhan virus vaccine candidate for assessment in a Phase 2 clinical study that is anticipated to begin in Q2 2023.
-
New Canadian Surveys Highlight Influenza Education, Discussions with Healthcare Professionals, and Ease of Access as Critical to Supporting Vaccination Uptake
9/29/2022
CSL Seqirus, a business of CSL Limited, announced new data from two Canadian studies investigating influenza vaccination uptake, perceptions about influenza, and the importance of vaccination.
-
New Data at OPTIONS XI Conference Highlight Burden of Seasonal Influenza on Health Systems and the Need for Increased Vaccination Rates
9/26/2022
CSL Seqirus, a business of CSL Limited (ASX:CSL), today announced new data highlighting the significant burden influenza places on hospitals and healthcare resource use, as well as on more vulnerable populations such as children.
-
Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2022/23 U.S. Season
7/11/2022
Seqirus, a global leader in influenza prevention and a business of CSL Limited, announced that it has begun to ship its portfolio of innovative cell-based, adjuvanted and egg-based seasonal influenza vaccines across the U.S. in preparation for the 2022/23 influenza season.
-
Seqirus Completes $156 Million Expansion to Holly Springs Manufacturing Facility, Optimizing Global Manufacturing Capabilities for Seasonal and Pandemic Influenza Vaccines
6/6/2022
Seqirus, a global leader in influenza prevention and a business of CSL Limited, announced the completion of an expansion to the company's manufacturing facility in Holly Springs, N.C., supporting the formulation and fill-finish of its cell-based influenza vaccines in pre-filled syringes for global communities.
-
It was a particularly busy week for clinical trial announcements. Let's take a look. -
Seqirus and U.S. Government Renew Multi-Year Agreement for Influenza Pandemic Preparedness and Response
2/25/2022
Seqirus announced the renewal of a five-year agreement with the Biomedical Advanced Research and Development Authority, a division of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services.
-
Seqirus, a Business of CSL Limited, Announces New Facility Supporting Research & Development of Leading-Edge Influenza Vaccine Technology
2/7/2022
Seqirus, a global leader in influenza prevention and a business of CSL Limited, announced an investment in a new Research and Development facility located in Waltham, Mass.
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace. -
Seqirus Presents New Real-World Evidence Supporting Effectiveness of Differentiated Seasonal Influenza Vaccine Technologies at ISIRV-WHO Virtual Conference 2021
10/19/2021
Seqirus today announced new real-world evidence (RWE) supporting the effectiveness of its cell-based and adjuvanted seasonal influenza vaccines.
-
Clinical Catch-Up: October 11-15
10/18/2021
It was yet another busy week for clinical trial announcements. Take a look. -
Seqirus Receives FDA Approval of its Cell-Based Quadrivalent Influenza Vaccine, Expanding the Age Indication to Include Children as Young as Six Months
10/15/2021
Seqirus today announced that the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX® QUADRIVALENT
-
Seqirus Presents New Real-World Evidence Demonstrating Effectiveness of Cell-Based and Adjuvanted Seasonal Influenza Vaccines at IDWeek 2021
9/29/2021
Seqirus today announced data supporting the effectiveness of both cell-based and adjuvanted seasonal influenza vaccines from two real-world studies conducted during the 2019/2020 influenza season in the U.S.
-
COVID-19 Booster Shots, the Flu and You
8/23/2021
While last flu season saw fears of a “twindemic” go largely unfounded, there are fears that recent lockdowns could also lead to a lack of natural immunity against the flu. -
Seqirus Announces Investment in Next-Generation Influenza Vaccine Technology, Self-Amplifying Messenger RNA (sa-mRNA)
8/19/2021
Seqirus today announced plans to accelerate the development of its next generation of messenger RNA (mRNA) vaccine technology
-
New Jersey-based Seqirus is expanding and accelerating its capabilities to develop next-generation self-amplifying mRNA (sa-mRNA) vaccines for influenza and other viral illnesses. -
Seqirus Presents New Real-World Evidence on Relative Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older at IDWeek 2020
10/21/2020
Seqirus, a global leader in influenza prevention, today presented new real-world evidence (RWE) on the effectiveness of an MF59 ® -adjuvanted, trivalent seasonal influenza vaccine (aTIV) in adults 65 years and older during the 2018/19 U.S. influenza season at the IDWeek 2020 virtual conference. 1 aTIV was found to be more effecti